Videos

In this discussion with Dr. Mease at ACR 2023, he covers findings on an assessment tool known as the PsA-5Ts for patients with psoriatic arthritis.

This interview segment with Dr. Mease featured a discussion about data presented at ACR 2023 on guselkumab and patients with psoriatic arthritis.

After a 12-week gap, 5% of patients returned to pegloticase and responded well.

This segment of Dr. Kivitz’s interview at ACR 2023 featured a discussion about future research on TAK-279 as well as general outlook on the field for psoriatic arthritis.

During this interview, Dr. Kivitz explained the background and key findings of his team’s research on TAK-279, a selective oral TYK2 inhibitor.

This interview segment with Dr. Fakih featured a discussion about his team’s findings and their methodology on the topic of spondyloarthritis.

In this discussion with Dr. Hunter, the findings his team presented at ACR 2023 were explored, including a discussion about their implications for the future of osteoarthritis treatment.

This discussion with Dr. Hunter covered the takeaways from his team’s phase 3 findings on treatment of osteoarthritis of the knee.

During this interview segment, Dr. Alevizos discussed some of the implications of his team’s findings regarding dazodalibep.

In this interview, Dr. Alevizos described the major takeaways from his team’s findings on this drug for Sjögren's Syndrome.

David Charles, MD, highlights how alternative funding programs, though well-intentioned, can inadvertently erode trust between patients and providers and cause delays in healthcare.

Stacie Bell, PhD, discusses the partnership between Lupus Therapeutics and AbbVie for the phase 3 clinical program of upadacitinib in patients with SLE, emphasizing the importance of collaboration and their role in accelerating the study process, recruitment, and the potential for meaningful advancements in lupus treatment.

V Michael Holers, MD, discusses the creation of Rheumatology Lab in response to a pressing need within the clinical practice community to provide an easily accessible resource for physicians to guide patients to valuable information.

Robert Edwards, PhD, discusses how cognitive behavioral therapy effectively reduced pain catastrophizing and improved quality of life in patients with fibromyalgia.

Ruth Napier, PhD, discusses her study revealing the crucial role the biomarker Card9 plays in the pathogenesis of ankylosing spondylitis.

The approval of the intravenous formulation of secukinumab allows healthcare providers to better tailor treatment to their patients’ unique needs. 

In this MEDcast episode, Drs. Soloman, Sharobeem, and Mease discuss newer mechanisms of actions and emerging therapies in rheumatic diseases and tools that are becoming available to rheumatologists to practice precision medicine.

Nehad Soloman, MD, believes acknowledging the cultural and social dynamics impacting patients' healthcare decisions and establishing a personal connection with patients can help overcome initial barriers to care.

JB Boone, MD, explains the progress being made towards more personalized medicine in patients with rheumatoid arthritis, as well as the current challenges.

JB Boone, MD, explains PrismRA, a predictive tool designed to determine whether a patient will likely have an inadequate response to a TNF inhibitor.

In this MEDcast episode, Drs Soloman, Sharobeem, Boone and Feldman discuss the use of step therapy in rheumatoid arthritis, how step therapy was intended to be used, how it is actually used, and challenges and solutions to its use.

Jeffrey Sparks, MD, MMSc, discusses what rheumatologists need to know about treating challenging cases of rheumatoid arthritis as well as the risks and benefits of more aggressive treatment strategies.

Experts conclude their discussion emphasizing the importance of integrative care and how providers can improve outcomes for their patients with fibromyalgia (FM).

Experts highlight current challenges in their practice treating patients with fibromyalgia (FM).

Experts discuss how they personalize treatments for patients with fibromyalgia (FM) and the importance of improving sleep in their approach.

Experts discuss the limited combination therapy options for the treatment of fibromyalgia (FM) and how to inform patients of prospective outcomes.

Experts discuss their step therapy approaches for the treatment of fibromyalgia (FM).

Experts discuss the long-term safety and efficacy of agents used for the treatment of fibromyalgia (FM).

Experts discuss the FDA approved agents duloxetine and pregabalin for the treatment of fibromyalgia (FM).

Experts discuss the FDA approved agent milnacipran for the treatment of fibromyalgia (FM).